Ipsen SA (IPN)

Currency in EUR
167.20
+10.00(+6.36%)
Closed·

IPN Earnings

Latest Release
Jul 30, 2026
EPS / Forecast
-- / --
Revenue / Forecast
1,12B / 1,03B
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/09--/----/------Free Sign Up
2026/06--/--1,12B/1,03B--+8,74%Free Sign Up
2026/03--/--1,07B/1,00B--+7%Free Sign Up
2025/121,32/--941,00M/974,20M---3,41%Free Sign Up
2025/09--/--915,00M/871,00M--+5,05%Free Sign Up
2025/064,00/--1,94B/917,00M--+111,56%Free Sign Up
2025/031,37/--918,80M/807,84M--+13,74%Free Sign Up
2024/121,37/--905,00M/882,10M--+2,6%Free Sign Up
2024/09--/--836,60M/835,85M--+0,09%Free Sign Up
2024/06--/--837,00M/852,17M---1,78%Free Sign Up

All numbers in EUR

Ipsen SA Earnings Call Summary for Q2/2026

  • Ipsen H1 2026 revenue hit $1.12B, beating $1.03B forecast by 8.74%; sales rose 23.5% at constant FX with growth across oncology, rare disease, neuroscience.
  • Core operating margin reached record 38.6%, up 2.5 points YoY; free cash flow surged 34.9% to €652M with net cash position rising to €1B from €555M in Dec 2025.
  • Company raised FY 2026 guidance to >20% sales growth from 13% prior, operating margin target lifted to >37% from >35%, citing delayed generic competition.
  • Dysport became first botulinum toxin with positive Phase III results in both episodic and chronic migraine; Iqirvo peak sales estimate raised to €1B in primary biliary cholangitis.
  • Management expects 2027 margin pressure from higher R&D and commercial spending ahead of Dysport migraine launch, but remains confident in midterm growth trajectory through 2027.
Last Updated: 2026/07/30, 15:16
Read Full Transcript

FAQ

What Is Ipsen's Earnings Per Share (TTM)?

The Ipsen EPS (TTM) is 5,37.

When Is The Next Ipsen Earnings Date?

Ipsen will release its next earnings report on Oct 16, 2026.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.